Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
In re Vaxart, Inc. Securities Litigation
Case Number:
3:20-cv-05949
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
- Akin Gump
- Baker Botts
- Berman Tabacco
- Bleichmar Fonti
- Boies Schiller
- Conrad Metlitzky
- Goodwin Procter
- Hagens Berman
- Hanson Bridgett
- Paul Hastings
- Robbins LLP
- Scott&Scott
- Thompson Hine
- Willkie Farr
- Wilson Elser
Companies
Sectors & Industries:
-
August 24, 2020
Biotech Co. Lied About COVID-19 Vaccine, Investors Say
Investors in Vaxart Inc. accused the San Francisco-headquartered biotechnology company of lying about its COVID-19 vaccine candidate in order to inflate its stock price, according to a complaint filed Monday in California federal court.
- ← Previous
- 1
- 2
- Next →